杨胜勇
杨胜勇，教授，博士生导师。
人物介绍
2003年1月-2005年10月，加拿大卡尔加里大学研究助理，同时兼任Bayer公司高级研究员。
2005年10月通过985平台进入四川大学华西医院生物治疗国家重点实验室工作，主要从事药物分子设计方法、先导化合物优化、靶向药物设计、合成与开发等研究工作。
任职：
四川省药学会药物化学专委会 副主任委员。
四川省肿瘤学会靶向治疗专委会 委员。
《Pharmacology \u0026 Pharmacy》 编委。
《J. Amer. Chem. Soc.》 特邀审稿人。
《J. Med. Chem.》 特邀审稿人。
《Proteins》 特邀审稿人。
《J. Chem. Inf. Mod.》 特邀审稿人。
《J. Theor. Comput. Chem.》 特邀审稿人。
《Eur. J. Med. Chem.》 特邀审稿人。
《Bioorg. Med. Chem. Lett.》 特邀审稿人。
研究方向
(1) 新型抗肿瘤靶向药物的研发。
(2) 新型治疗自体免疫性疾病疾病药物的研发。
(3) 先导化合物优化与合成研究。
(4) 药物分子设计新方法研究。
(5) 系统生物学。
主要贡献
主持了包括863、国家创新药物重大专项、国家自然科学基金、教育部新世纪优秀人才资助计划、四川省杰出青年基金等多项国家和省部级项目。至今已在包括白血病, J. Amer. Chem. Soc., Clinica Cancer Res., Drug Disc. Today, J. Med. Chem., Plos ONE, Proteins, J. Comput. Chem., Organometallics, J. Phys. Chem. A 等国内外重要期刊上发表SCI研究论文100余篇。曾获四川省科技进步奖一项。研究领域：计算机辅助药物分子设计；计算生物学。
代表性论著：
支姓 Cao, Jing-Jing Liu, Ren-Lin Zheng, Jiao Yang, Lei Zhong, Yong Xu, Li-Jiao Wang, Chun-Hun Zhang, Bing-Lin Wang, Shuang Ma, Huan-Zhang Xie, Yu-Quan Wei, and Sheng-Yong Yang*. SKLB1028, a novel oral multikinase inhibitor of EGFR, FLT3 and Abl, displays exceptional activity in models of FLT3-driven AML and considerable 效价强度 in that of 化学标记语言 harboring 东南亚职业篮球联赛 mutants. Leukemia, 2012. In press。
Li WW, Wang XY, Zheng RL, Yan HX, Cao ZX, Zhong L, Wang ZR, Ji P, Yang LL, Wang LJ, Xu Y, Liu JJ, Yang J, Zhang CH, Ma S, Feng S, Sun QZ, Wei YQ, Yang SY*. Discovery of the Novel Potent and Selective FLT3 Inhibitor 1-{5-[7-(3- Morpholinopropoxy) quinazolin-4-ylthio]-[1,3,4] thiadiazol-2-yl} -3-p-tolylurea and Its Anti-Acute Myeloid 白血病 (AML) Activities in Vitro and in vivo J Med Chem. 2012, 55, 3852-3866。
Youli pan, Yong Xu, Shan Feng, Shidong Luo, Renlin Zheng, Jiao Yang, Lijiao Wang, Lei Zhong, Han-Yu Yang, Bing-Lin Wang, Yang Yu, Jingjing Liu, Zhixing Cao, Xiaoyan Wang, Pan Ji, Zerong Wang, Xin Chen, Shuang Zhang, Yu-Quan Wei, and Sheng-Yong Yang*. SKLB1206, a Novel Orally Available Multikinase Inhibitor Targeting EGFR Activating and T790M Mutants, ErbB2, ErbB4, and VEGFR2, Displays Potent Antitumor Activity both In vitro and In vivo Mol Cancer Ther. 2012, 11(4), 952-962。
Wan HL, Wang ZR, Li LL, Cheng C, Ji P, Liu JJ, Zhang H, Zou J, Yang SY*.Discovery of novel Bruton's tyrosine kinase (Btk) inhibitors using a hybrid protocol of virtual screening approaches based on SVM model, pharmacophore, and molecular docking. Chem Biol Drug Des. 2012. doi: 10.1111/j.1747-0285 2012.01415.x。
Di-Wu L, Li LL, Wang WJ, Xie HZ, Yang J, Zhang CH, Huang Q, Zhong L, Feng S, Yang SY*。Identification of CK2 inhibitors with new scaffolds by a hybrid virtual screening approach based on Bayesian model; pharmacophore hypothesis and molecular docking. J 摩尔 Graph Model. 2012, 36, 42-47。
Xiao-Yu Qing, Chun-Hui Zhang, Lin-Li Li, pan Ji, Shuang Ma, Hua-Lin Wan, Ze-Rong Wang, Jun Zou, and Sheng-Yong Yang*. Retrieving Novel C5aR Antagonists using a Hybrid 配体based Virtual Screening Protocol based on SVM 分级 and Pharmacophore Models. J Biomol Struct Dyn. 2012, in press。
Zhong L, Ma CY, Zhang H, Yang LJ, Wan HL, Xie QQ, Li LL, Yang SY* A prediction model of substrates and non-substrates of breast cancer 厚膜电阻 proTEIN (BCRP) developed by GA-CG-SVM method. Comput Biol Med. 2011 Nov;41(11):1006-13。
Huang Q, Li LL, Yang SY*. RASA: a rapid retrosynthesis-based scoring method for the assessment of synthetic accessibility of drug-like molecules.J Chem Inf Model. 2011 Oct 24;51(10):2768-77。
Zhou JP, Chen X, Feng S, Luo SD, pan YL, Zhong L, Ji P, Wang ZR, Ma S, Li LL, Wei YQ, Yang SY* Systems Biology Modeling Reveals a Possible Mechanism of the Tumor 细胞 死亡 upon 癌基因 Inactivation in EGFR Addicted Cancers.PLoS One. 2011;6(12):e28930。
Ren JX, Li LL, Zheng RL, Xie HZ, Cao ZX, Feng S, pan YL, Chen X, Wei YQ, Yang SY* Discovery of novel Pim-1 kinase inhibitors by a hierarchical multistage virtual screening approach based on SVM model, pharmacophore, and molecular docking. J Chem Inf Model. 2011 Jun 27;51(6):1364-75。
Xie QQ, Zhong L, pan YL, Wang XY, Zhou JP, Di-Wu L, Huang Q, Wang YL, Yang LL, Xie HZ, Yang SY* Combined SVM-based and docking-based virtual screening for retrieving novel inhibitors of c-Met. Eur J Med Chem. 2011, 46, 3675-3680。
[12]Zhang H, Li W, Xie Y, Wang WJ, Li LL, Yang SY*. Rapid and accurate assessment of 癫痫发作 liability of drugs by using an optimal support 向量 machine method. Toxicol In Vitro. 2011,25,1848–1854。
Xie HZ, Liu LY, Ren JX, Zhou JP, Zheng RL, Li LL, Yang SY*. Pharmacophore modeling and hybrid virtual screening for the discovery of novel IκB kinase 2 (IKK2) inhibitors. J Biomol Struct Dyn. 2011, 29(1):165-79。
Dong X, Ebalunode JO, Yang SY, Zheng W. 捕手based pharmacophore and pharmacophore key descriptors for virtual screening and QSAR modeling. Curr Comput Aided Drug Des. 2011 Sep 1;7(3):181-9。
[15]Zeng XF, Li WW, Fan HJ, Wang XY, Ji P, Wang ZR, Ma S, Li LL, Ma XF, Yang SY* Discovery of novel fatty acid synthase (FAS) inhibitors based on the structure of ketoaceyl synthase (KS) 蛋白质结构域 Bioorg Med Chem Lett. 2011 Aug 15;21(16):4742-4。
Guo-Bo Li, Ling-Ling Yang, Shan Feng, Jian-Ping Zhou, Qi Huang, Huan-Zhang Xie, Lin-Li Li, Sheng-Yong Yang*. Discovery of novel mGluR1 antagonists: A multistep virtual screening approach based on an SVM model and a pharmacophore hypothesis significantly increases the hit rate and enrichment factor. Bioorg Med Chem Lett. 2011 Jan 25. [Epub ahead of print]。
Jun Zou,Shi-Dong Luo,Yu-Quan Wei and Sheng-Yong Yang*, Integrated computational model of cell cycle and checkpoint reveals different essential roles of 极光-A and Plk1 in mitotic entry. 摩尔 BioSyst., 2011, 7, 169–179。
Qi Huang, Lin-Li Li, Sheng-Yong Yang*. PhDD: A new pharmacophore-based de novo 设计 method of drug-like molecules combined with assessment of synthetic accessibility. Journal of Molecular Graphics and Modelling. 2010, 28, 775-787。
Wei-Wei Li, Jin-Juan Chen, Ren-Lin Zheng, Wen-Qin Zhang, 支姓 Cao, Ling-Ling Yang, Xiao-Yu Qing, Liang-Xue Zhou, Li Yang, Luo-Ding Yu, Li-Juan Chen, Yu-Quan Wei, and Sheng-Yong Yang*. Taking quinazoline as a general support-nog to 设计 potent and selective kinase inhibitors: application to FMS-like tyrosine 激酶 3. ChemMedChem. 2010, 5, 513-516。
Sheng-Yong Yang*. Pharmacophore modeling and applications in drug discovery: challenges and recent advances. Drug Discovery Today. 2010, 15, 444-450。
Li-Jun Yang, Jun Zou, Huan-Zhang Xie, Lin-Li Li, Yu-Quan Wei, Sheng-Yong Yang*. Steered molecular 动力学 simulations reveal the likelier dissociation 神经通路 of imatinib from its targeting kinases c-Kit and 东南亚职业篮球联赛 PLOS One. 2009, 4, e8470。
Ji-Xia Ren, Lin-Li Li, Jun Zou, Li Yang, Jin-Liang Yang, Sheng-Yong Yang*. Pharmacophore modeling and virtual screening for the discovery of new transforming growth factor-b type I receptor (ALK5) inhibitors. European Journal of Medicinal 化学. 2009, 44, 4259-4265。
Huan-Zhang Xie, Lin-Li Li, Ji-Xia Ren, Jun Zou, Yu-Quan Wei, and Sheng-Yong Yang*. Pharmacophore modeling study based on known spleen tyrosine kinase inhibitors together with virtual screening for identifying novel inhibitors. Bioorganic \u0026 Medicinal Chemistry Letters. 2009, 19, 1944-1949。
Jin-Juan Chen, Ting-Lin Liu, Li-Jun Yang, Lin-Li Li, Yu-Quan Wei and Sheng-Yong Yang*. Pharmacophore modeling and virtual screening studies of checkpoint kinase 1 inhibitors. Chem. Pharm. Bull. 2009, 57, 704-709。
Sheng-Yong Yang*, Qi Huang, Lin-Li Li, 常姓Ying Ma, Hui Zhang, Ru Bai, Qi-Zhi Teng, Ming-Li Xiang, Yu-Quan Wei. An integrated 概形 for feature selection and parameter setting in the support 向量 machine modeling and its application to the prediction of pharmacokinetic properties of drugs. Artificial Intelligence in Medicine. 2009, 46, 155-163。
Hui Zhang, Ming-Li Xiang, 常姓Ying Ma, Qi Huang, Wei Li, Yang Xie, Yu-Quan Wei, Sheng-Yong Yang*. Three-class 分级 models of logS and logP derived by using GA-CG-SVM approach. Molecular Diversity 2009, 13, 261-268。
Lijun Yang, Ruo Jia, Sheng-Yong Yang*. Influence of the solvent H₂O molecules at the active site of CDK2 on the binding free 能量 of CDK2-配体 complexes: an MM/PBSA study. Acta Chimica Sinica. 2009, 67, 255-260。
Hui Zhang, Qing-Yi Chen, Ming-Li Xiang, 常姓Ying Ma, Qi Huang and Sheng-Yong Yang*. In silico prediction of mitochondrial 毒性 by using GA-CG-SVM approach. Toxicity in vitro, 2009, 23, 134–140。
Hui-Yuan Wang, Lin-Li Li, 支姓 Cao, Shi-Dong Luo, Yu-Quan Wei and Sheng-Yong Yang*. A specific pharmacophore model of Aurora B 激酶 inhibitors and virtual screening studies based on 信息技术 Chemical Biology \u0026 Drug 设计 2009, 73(1), 115-126。
Ting-lin Liu, Huan-zhang Xie, Yu-quan Wei, Sheng-Yong Yang*. Exploring the feasibility of application of reverse docking method to the selectivity studies of protein 激酶 inhibitors.Acta Pharmaceutica Sinica. 2009, 44(7), 758-763。
Qing-Qing Xie, Huan-Zhang Xie, Jie-Xia Ren, Lin-Li Li, and Sheng-Yong Yang*. Pharmacophore modeling studies of type I and type II kinase inhibitors of Tie2. Journal of Molecular Graphics and Modelling. 2009, 27, 751–758。
Hui Zhang, Ming-Li Xiang, Ying-Lan Zhao, Yu-Quan Wei and Sheng-Yong Yang*. Support vector machine and pharmacophore-based prediction models of multidrug-厚膜电阻 protein 2 (MRP2) inhibitors. European Journal of Pharmaceutical Sciences. 2009, 36, 451–457。
获得荣誉
2023年8月31日，入选2023年中国科学院院士增选有效候选人名单。
参考资料
关于公布2023年中国科学院院士增选有效候选人名单的公告.中国科学院.2023-09-02